Dr Vanessa Lattimore
The ideal strategy for controlling and reducing the social impact of disease is effective prevention.
Using Deep Learning And Digital Pathology To Intrinsically Subtype Breast Cancer
Dr Gavin Harris
Digital pathology is the reviewing of tissue slides on a computer monitor rather than using microscopes.
Validation Of Predictive Biomarkers For T-DM1 Activity In HER2+ Breast Cancer
Dr Barbara Lipert
The antibody-drug conjugate trastuzumab emtansine (T-DM1; Kadcyla) extends the survival of HER2-positive metastatic breast cancer patients.
Analysis Of Full-length Transcripts For Variant Classification In Breast Cancer
Dr Logan Walker
The future of successful genetic screening in New Zealand requires increased sensitivity and specificity of tests, and informed clinical management for high-risk breast cancer families.
Validation Of A Liquid Biopsy To Predict Recurrence In NZ Breast Cancer Patients
Dr Annette Lasham
Early detection of breast cancer recurrence is critical for saving lives. We have identified two molecules, found in the blood of 250 patients at the time of surgery for breast cancer, that were very good at predicting which of these women would have a relapse before five years.
Preventing Breast Cancer Metastasis With Conjugate Vaccines Targeting Human HER2
Dr Robert Weinkove
The aim of this novel and ambitious project is to develop potent new vaccines with potential to prevent recurrence of HER2 positive breast cancer.
Targeting HIF-1 In Triple Negative Breast Cancer Using Glutaminase Inhibitors
Dr Dean Singleton
It is now understood that Triple Negative breast cancer has many biologic nuances and a heterogeneity not previously understood.
Targeting Breast Cancer Metastasis With Heparan Sulfate Mimetics
Professor John Miller
This research team combines leading expertise in synthetic and medicinal chemistry and cancer biology.
Investigating Fn14 As A Driver Of Breast Cancer Metastasis
Dr Heather Cunliffe
The presence of a protein called Fn14 on the surface of 75% of invasive breast cancers, has been shown to be strongly prognostic for distant metastasis, with the strongest association in HER2/neu positive and Triple Negative breast cancers.
The potential of immunotherapy as a treatment for ER+ve breast cancer
Dr Anita Dunbier
Treatments that stimulate the immune system to attack tumours have revolutionised the treatment of some cancer types.